Viewing data from:

EPIFOAM

ANDA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE | A086457 | MYLAN SPECIALTY LP

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Epifoam (2023)

Total Spending

$13K

Total Claims

117

Beneficiaries

Avg Cost/Unit

$9.53

Spending Trend

$5K(2021)→$12K(2022)→$13K(2023)

YoY Change:+8.9%

5yr CAGR:+7.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 1%;1%

0 patents0 exclusivities▴

AEROSOL, METERED;TOPICAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.